I'm a thoracic oncologist specializing in the care of patients with lung cancer, mesothelioma, and thymic cancers. My research is focused on advancing experimental therapeutics, precision oncology, and biomarker-driven treatment strategies through both investigator-initiated and multicenter clinical trials to improve outcomes for patients with lung cancer and other thoracic malignancies. I serve as site principal investigator and collaborator on numerous national and industry-sponsored studies and have led or collaborated on several investigator-initiated studies contributing to the development of next-generation treatment approaches. Additional research interests involve process improvement modeling for clinical outcomes and cost effectiveness.
- BS, Microbiology, The Ohio State University, 2008
- MD, St. George's University, 2015
- Residency, Internal Medicine, Medical College of Georgia/Augusta, 2018
- Post-doctoral Fellowship, Patient Safety, University of Florida College of Medicine-Jacksonville, 2019
- Fellowship, Hematology/Oncology, Cleveland Clinic Foundation, 2022
Education & Training
Lemmon CA, Zhou J, Hobbs B, Pennell NA. Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States. JCO Precis Oncol. 2023 Jan;7:e2200294. PMID: 36634300.
Lemmon CA, Videtic G, Murthy S, et al.A phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer. JTO Clinical and Research Reports. 2022 Jun 15;3(7):100359. PMID: 35815318
Lemmon CA, Zabor EC, Pennell NA. Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer. Oncologist. 2022 May 6;27(5):407-413. PMID: 35285487
